The vagus nerve stimulation market size is estimated to be USD 485.12 million in 2022 and is expected to witness a CAGR of 10.87% during the forecast period 2023-2033. Rising prevalence of neurological conditions including epilepsy, depression, and migraines and increasing use of less invasive neurosurgery techniques are factors contributing to the market growth. Additionally, growing number of approvals and new product launches are expected to support the market growth. However, increase in the price of VNS devices is expected to hinder the growth.

Rising prevalence of neurological conditions including epilepsy, depression, and migraines is expected to fuel the market growth during the projected period. According to the WHO, neurological diseases account for 6.3% of the world’s disease burden and are a leading cause of death globally, affecting 13.2% of people in developed nations and 16.8% of people in low- and middle-income nations. Clinical urgency arises for the adoption of long-term remedies such vagus nerve stimulators due to high mortality and disease burden. In 2019, the WHO estimates that there are more than 50 million epileptics worldwide. VNS therapy can be used as an additional treatment to reduce seizures even while epilepsy can be controlled with drugs.

Growing number of approvals and new product launches is predicted to propel the market growth during the forecast period. The FDA has approved an implantable VNS for the management of depression and epilepsy. A novel non-invasive VNS device that can treat pain, depression, and epilepsy without requiring surgical implantation has also been approved in Europe. For instance, LivaNova’s Symmetry VNS Therapy System for difficult-to-treat depression obtained the CE Mark approval in March 2020.

Segmentation

By Product

The market is categorized into external VNS device and implantable VNS device. In the global market, the implantable VNS device segment accounted for the largest revenue share in 2022 owing to the surge in the number of patients with epilepsy, depression, and various headache problems. The implanted VNS devices are designed to target the pain site specifically and change nerve activity by electrically stimulating a specific nerve, making this method of treatment more efficient. For people who have not responded to anti-seizure medicine and intense depression treatments including electroconvulsive therapy, psychotherapy, and antidepressants, an implantable VNS device may be useful. Furthermore, the demand for and uptake of VNS devices in the global market is being propelled by the launch of new and innovative products by major industry competitors. For instance, the FDA authorized the MicroTransponder Vivistim Paired VNS System in August 2021. This drug rehabilitation system is intended to treat moderate to severe upper extremity motor impairments caused on by chronic ischemic stroke.  The external VNS device market is anticipated to grow at the highest CAGR. The demand for these devices is expected to increase during the forecast period due to the introduction of new technologies by market participants and a shift in patient preference toward non-invasive devices.

By Biomaterial

The market is divided into polymeric, metallic, and ceramics. In 2022, the metallic segment accounted for the highest revenue share due to developments and expansion in the R&D for vagus nerve stimulation therapies. Metallic biomaterials are most frequently employed in implantable medical devices due to high mechanical & thermal conductivity. Some of the metals used for coating electrical implanted devices due to their anti-inflammatory qualities include 316L stainless steel, titanium-based alloys, gold, tantalum, silver, platinum, and cobalt-chromium alloys. The polymeric segment is anticipated to increase at the highest pace due to the advantages of flexibility. Rising cases of stress and depression globally. Polymers are able to regenerate injured brain tissues and can be formed into support structures such as electro-spun matrices, nerve conduits, and scaffolds. Medical implanted devices are made of polymers as they have a wide variety of forms and mechanical properties, including bioactivity and biocompatibility. These factors are anticipated to fuel segment growth over the course of the projection period.

By Application

The market is segregated into migraine, epilepsy, and depression. In the global market, the epilepsy segment accounted for the largest revenue share in 2022 owing to rising number of regulatory approvals and the significant global prevalence of epilepsy. For instance, according to the WHO, 139 people are diagnosed with epilepsy each year in low- and middle-income nations, compared to 49 persons out of 100,000 in high-income countries. Similar to adults, 100,000 to 120,000 children are admitted to hospitals in the United States each year due to conditions related to epilepsy. The segment is anticipated to grow as a result in the upcoming years. Strategic alliances and increased levels of knowledge about epilepsy treatment are also expected to boost market expansion. The demand for improved diagnosis and efficient treatment of the disease has increased as a result of epilepsy networks’ awareness-raising campaigns. For instance, to increase awareness of epilepsy around the world, the Epilepsy Association of Nova Scotia and the Anita Kaufmann Foundation officially announced March 26 as “Purple Day” in 2009. The depression market is estimated to expand at the fastest CAGR. The burden of difficult-to-treat depression impacts more than 2.7 million American people, according to the National Institute of Mental Health (NIHM). Additionally, according to the WHO, more than 300 million adults worldwide suffer from depression, and about one-third of people with major depressive disorder (MDD) have depression that is resistant to therapy (TRD).

By End Use

The market is segmented into neurology clinics, hospitals, research centres, ambulatory surgical centres, and others. In 2022, the hospitals segment accounted for the largest revenue share owing to increase in hospital-performed VNS procedures and a rise in the prevalence of neurological disorders. Furthermore, it is anticipated that the hospitals segment would grow throughout the projected period due to the accessibility of technologically advanced gadgets and advantageous reimbursement policies. Medtronic, for instance, provides thorough services to establish and maintain coverage and payment for various DBS devices. In addition, hospitals are currently improving technologically, and advanced devices are widely used in hospitals to provide better care. These technologies assist produce better, faster, and more accurate outcomes in addition to streamlining treatment methods. Most neurological conditions, including epilepsy, are diagnosed and treated by qualified neurologists who work in specialised facilities with cutting-edge technology. The Ambulatory Surgical Centers (ASC) market is anticipated to grow at the highest CAGR. This is due to the procedures are less expensive compared to hospital procedures, patient care is more easily accessible, waiting times are shorter, and infection rates are lower compared to hospitals and neurology clinics.

Regional Markets

In 2022, North America region accounted for the highest revenue in the vagus nerve stimulation market and is expected to maintain its dominance during the forecast period. This is attributed to the higher government spending and regional campaigns to promote public awareness of epilepsy and difficult-to-treat depression. A number of other important factors, including fast technological development, presence of major manufacturers in the area, upsurge in R&D expenditures, and an increase in the number of government funding and initiatives are anticipated to generate significant growth opportunities in the market. For instance, the Centers for Medicare & Medicaid Services (CMS) estimates that U.S. health spending would increase by 5.5% year between 2018 and 2027 and total USD 6 trillion by that year. The high level of disposable income in developed economies and the accessibility of qualified specialists are further factors that contribute to the North American region’s dominant market share. However, Asia Pacific is anticipated to have rapid growth. This is due to the region’s increasing frequency of neurodegenerative diseases and the unmet need for long-lasting remedies. Market expansion in this region is anticipated to be propelled by increasing consumer knowledge of available treatments for neurological diseases and advancements in emerging economies’ clinical development frameworks. Additionally, the existence of high-growth potential in developing countries such as Japan, China, and India are certainly going to support market expansion. Moreover, it is expected that the establishment of institutions such as the Asia-Pacific Centre for Neuromodulation (APCN), which was formed to conduct research and raise awareness about the advantages of vagus nerve stimulation, will promote regional growth.

Competitor Insights

Some of the key players operating in the vagus nerve stimulation market are Cerebral Rx, Brain Control Co. Limited, LivaNova PLC, Soterix Medical Inc., electroCore, Inc., Cirtec, MicroTransponder Inc, Medtronic, Parasym Ltd, SetPoint Medical, and tVNS Technologies GmbH among others.

To achieve a competitive edge, these companies are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by companies in this sector.

• For instance, LivaNova’s Symmetry VNS Therapy System for difficult-to-treat depression gained the CE Mark approval in March 2020.
• For instance, electroCore completed its Series B Funding round with about USD 70 million in November 2017. This funding was used to commercialize gammaCore and further the clinical development of nVNS.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including product, biomaterial, application, and end use from 2023 to 2033.

Report Scope:

Segmentation: Vagus Nerve Stimulation Market Report 2022 – 2033

Product (Revenue, USD Million), 2022 – 2033

• External VNS Device
• Implantable VNS Device

Biomaterial (Revenue, USD Million), 2022 – 2033

• Polymeric
• Metallic
• Ceramics

Application (Revenue, USD Million), 2022 – 2033

• Migraine
• Epilepsy
• Depression

End Use (Revenue, USD Million), 2022 – 2033

• Neurology Clinics
• Hospitals
• Research Centres
• Ambulatory Surgical Centres
• Others

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA